N-(3-(2-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl)phenyl)methanesulfonamide | 1454654-49-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-(3-(2-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl)phenyl)methanesulfonamide
• 英文别名: N-[3-[2-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]phenyl]methanesulfonamide
• CAS: 1454654-49-9
• 化学式: C₂₄H₂₈N₈O₂S
• 分子量: 492.605
• InChiKey: MGHNGKOXSFRVLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• [EN] TRIAZOLOPYRAZINE DERIVATIVES<br/>[FR] DÉRIVÉS DE TRIAZOLOPYRAZINE
  申请人：MERCK PATENT GMBH

  公开号：WO2013131609A1

  公开（公告）日：2013-09-12

  Compounds of the formula (I) in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.

  式(I)中R1、R2和R4具有权利要求1中所指示的含义的化合物是GCN2的抑制剂，可用于治疗癌症。
• TRIAZOLOPYRAZINE DERIVATIVES
  申请人：Merck Patent GmbH

  公开号：US20150051202A1

  公开（公告）日：2015-02-19

  Compounds of the formula I in which R 1 , R 2 and R 4 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.

  公式I中，R1、R2和R4的含义如权利要求1所示的化合物是GCN2的抑制剂，可以用于治疗癌症等疾病。
• [EN] EXTRACT FORMULATIONS OF RHODAMNIA CINEREA AND USES THEREOF<br/>[FR] FORMULATIONS EXTRAITES DE RHODAMNIA CINEREA ET UTILISATIONS CORRESPONDANTES
  申请人：BIOTROPICS MALAYSIA BERHAD

  公开号：WO2013133685A1

  公开（公告）日：2013-09-12

  The present invention primarily relates to the use of certain extract formulations of Rhodamnia cinerea as defined herein as alpha-amylase inhibitors and as actives for the therapeutic (including prophylactic) treatment of a carbohydrate metabolic disorder or of a disease attendant on hyperglycemia, preferably selected from the group consisting of prediabetes, obesity, hyperlipemia, arteriosclerosis, arteriolosclerosis, atherosclerosis, diabetes, postprandial hyperglycemia, and metabolic syndrome. The present invention also relates to corresponding methods. The invention further relates to specific extract formulations obtainable from Rhodamnia cinerea and to compositions, in particular orally consumable compositions, comprising an effective amount of such an extract formulation.